上市捷报丨沙利文祝贺上海奥浦迈生物科技股份有限公司成功登陆科创板(688293.SH)

Shanghai Aopuima Biotechnology Co., Ltd. (Stock Code:688293.SH) on2022year9month2The company successfully listed on the Sci-tech Innovation Board. It is a high-tech enterprise specializing in cell culture products and services, providing customers with holistic solutions by organically integrating cell culture products and services. Frost & SullivanFrost & Sullivan,Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan') hereby warmly congratulates the company on its successful listing.

Shanghai Aopuima Biotechnology Co., Ltd. (hereinafter referred to as 'Aopuima') was established on2022year9month2The company was successfully listed on the stock market, with an issue price of80.20yuan/shares, total issuance8,19810,000 shares.

Opmira is a high-tech enterprise specializing in cell culture products and services. Based on excellent cell culture technology and production processes, the company provides cell culture medium products andCDMOCombining services accelerates the process of new drug research and development applications; by optimizing products and processes, pharmaceutical costs are reduced, contributing to the rapid development of the biopharmaceutical industry. In China, cell culture media have long relied on imports, especially in the field of serum-free medium formulations and technology, which has greatly affected the development of biological products in our country. The company focuses on the research and development and production of culture media for antibodies and vaccines, establishing large-scale compliance withGood Manufacturing PracticeThe required culture medium production base has developed a variety of culture medium products that can replace imported brands and has achieved commercial sales. These products are widely used in protein/Biological product production fields such as antibody production, vaccine production, cell therapy, and gene therapy.

Overall development overview of the pharmaceutical industry

Under the combined influence of factors such as accelerating aging, increased social healthcare expenditures, and rising R&D investment, the global pharmaceutical market has maintained stable growth in the past.2020The global pharmaceutical market size is12,988billion US dollars, expected in2025Annual achievement17,114billion US dollars, with an annual compound growth rate of5.7%Among them, the United States and China remain the world's top two pharmaceutical markets at present. Compared with other regions of the world, they show rapid growth rates. The development of the pharmaceutical outsourcing market has greatly accelerated the R&D progress of pharmaceutical companies.

Global pharmaceutical market by region2016-2025E

Source: Frost & Sullivan report

The Chinese pharmaceutical market consists of three parts: chemical drugs, biopharmaceuticals, and traditional Chinese medicine. In terms of market share, chemical drugs account for a relatively high proportion, while biopharmaceuticals account for a lower proportion. From the perspective of growth rate, the growth rate of biopharmaceuticals is much higher than that of chemical drugs and traditional Chinese medicine. Calculated by revenue,2016Year-end2020The annual compound growth rate for the year reached17.1%The biopharmaceutical market is expected to be2025Annual achievement8,116RMB 10 billion2020Year to2025The annual compound growth rate for the year is expected to be18.6%.

The scale of the Chinese pharmaceutical market is split into chemical drugs and biopharmaceuticals

2016 - 2025E

Source: Frost & Sullivan report

Overview of the Biopharmaceutical and Antibody Market

Globally, the pharmaceutical market can be mainly divided into two categories: biopharmaceuticals and chemical drugs. Biopharmaceuticals can be further subdivided into multiple categories. Currently, gene and cell therapy, as well as antibody-based drugs, are two sub-sectors with significant potential for new drug launches in the short term. At the same time, vaccines, with their solid market foundation, will also maintain stable and rapid development in the future.

Compared to the production of traditional pharmaceuticals, the production of biologics is generally more difficult and complex. During the production process of biologics, it is necessary to set parameters and control conditions specifically and precisely. A slight change in any link can cause changes in the performance of biologics, such as immunogenicity, side effects, efficacy, etc. In addition to the effectiveness and safety of the drug itself, the large-scale commercial production of biologics cannot be separated from considerations of commercial factors such as cost and efficiency. Therefore, the importance of upstream process development and large-scale production of biologics is very prominent.

There are few types of monoclonal antibody drugs available in China, and their coverage rate is low.2017Year start,The national medical insurance system has significantly expanded the coverage of monoclonal antibody drugs.,This will increase the penetration rate of monoclonal antibody prescriptions in the future. At the same time,The introduction of immunotherapy products, for exampleOpdivo,KeytrudawaitPD-1The approval of inhibitors in China will further promote the expansion of the monoclonal antibody market in the country.2020In [year], the market size of monoclonal antibodies in China (including oncology and non-oncology indications) was411100 billion RMB, expected by2025year,The market will grow to1,9451000 million RMB2020Year-end2025The annual compound growth rate for36.5%.

The market scale of antibody drugs in China2016 - 2025E

Source: Frost & Sullivan report

According toCDEAccording to the registered clinical trials statistics, the number of clinical registrations for antibody drugs has also shown a rapid growth trend. Especially in2017After the landmark release of the 'Opinions on Deepening the Reform of the Evaluation and Approval System to Encourage Innovation in Drugs and Medical Devices', it greatly encouraged the enthusiasm for the research and development of antibody drugs.IIIThe number of ongoing clinical trial registrations has been2020Annual achievement127A sufficient pipeline of clinical research ensures an adequate reserve of antibody drugs for future market launch, indicating a huge demand for production materials (such as culture media, supplements, etc.) in the future.

Cell culture medium market overview

The most important and critical step in animal cell culture is the selection of an appropriate medium for in vitro cultivation. Cell culture has now become one of the main technologies applied in life sciences. It refers to the general term for culturing single cells dispersed from a biological organism into individual cells or directly taken from the organism, in an artificial environment conducive to growth. Growth media or culture solutions are liquid or gel-like substances designed to support the growth of microorganisms, cells, or small plants. Culture medium is the most important and complex factor in controlling optimal cell growth.

Animal cell culture can use either natural or synthetic media./The synthetic medium is mixed with some natural products. Artificial media can be divided into balanced salt solutions, basic media, and compound media according to their use; while based on proteins/The content of uncertain components such as peptide extracts can be categorized into serum-containing medium, low-serum medium, serum-free medium, protein-free medium, medium with identified chemical components, medium without protein but with identified chemical components, and protein-free./The certainty of the chemical composition in culture media containing peptides increases with the number of components identified.

Classification of cell culture media

Source: Frost & Sullivan report

The global biopharmaceutical market is mainly dominated by developed countries, which have entered a relatively stable market growth phase over the past few years. Correspondingly, the upstream culture medium market has also grown steadily.2020Annual achievement17A market scale of hundreds of millions of dollars,2016 - 2020The annual compound growth rate is8.6%In our country,2020In China, the market scale of culture media reached15.21000 million RMB2016 - 2020The compound annual growth rate for the year is32.3%estimated2025The market scale of cell culture media in China will reach54.41000 million RMB2020 - 2025The compound annual growth rate for the year is29.0%.

Market scale and forecast of cell culture media in China2016 - 2025E

Source: Frost & Sullivan report

Under the COVID-19 pandemic, the research and development of biopharmaceuticals, especially antibodies and vaccine products, has seen a surge, driving rapid growth in the sales of culture media.2020In [year], a series of domestic culture medium manufacturers achieved significant revenue growth. The overall market competition landscape has changed significantly compared to before the pandemic, with some imported manufacturers' market share being surpassed by several domestic manufacturers. In terms of market share trends, the proportion of domestic culture media has been increasing year by year. The market share of domestic culture media has risen from2016year18.6%Grew to2020year22.8%The increasing market share of domestic culture media is due, on the one hand, to the continuous improvement and refinement of the quality of domestic culture media, and on the other hand, to factors such as the flexible and efficient supply chain and marketing strategies of domestic culture media manufacturers in the local market.

Frost & Sullivan integrates globally.61years of consulting experience,24Frost & Sullivan has been dedicated to serving the booming Chinese market for years, demonstrating a global perspective in helping clients accelerate their business growth and achieve industry-leading benchmarks in terms of growth, innovation, and leadership. The health industry is one of the core areas of focus for Frost & Sullivan. Recently20For many years, the Frost & Sullivan team has provided financing and financial advisory services to hundreds of outstanding domestic and international biopharmaceutical, medical device, healthcare services, and internet healthcare companies.IPO listingIndustry consulting, strategic consulting, management consulting, and other services. Successful listings include: Biorotech2315.HK), Zhiyun Health9955.HK), MeinGene6667.HK),Prenetics（NASDAQ:PRE), Yunkang Group2325.HK), Ruike Biotechnology2179.HK), Leepu Biotech2157.HK), Clear Medical1406.HK), Baisinkan2185.HK), Yonghe Medical (2279.HK), Kailaiying6821.HK), Beihai Kangcheng1228.HK), Gusheng Hall2273.HK), Eagle Eye Technology2251.HK), Clover Biotechnology2197.HK), minimally invasive robots2252.HK), and Yuhuan Cayman2256.HK), Kunbo Medical (2216.HK), Xianruida6669.HK), Kangsheng Global9960.HK), Medical Pulse Connect (2192.HK), Tengsheng Bo Pharmaceutical2137.HK), Conoco (2162.HK), Chaogju Eye Hospital (2219.HK), Guichuangtong Bridge2190.HK), and Huang Medicine0013.HK), Keji Pharmaceutical2171.HK), Zhaoke Eye Hospital6622.HK), Nature MedicineUPC.NASDAQ), Sino Biologics (6600.HK), Zhaoyan New Drugs6127.HK), Novo Nordisk Health (6606.HK), Tianyan PharmaceuticalADAG.NASDAQ), Beikang Medical (2170.HK), Jianbaimiao Miao Miao2161.HK), Minimally Invasive Cardiac Angioplasty (2160.HK), Ruili Medical Beauty2135.HK), Jiake Pharmaceutical1167.HK), and Bopan Medicine2142.HK), JD Health6618.HK), Deqi Medicine6996.HK), Rongchang Biology9995.HK), WuXi AppTec Genomics (2126.HK), XianSen Pharmaceutical2096.HK), Yunding Xinyao1952.HK), Harvest Biotech6998.HK), ZaiDi Medical (9688.HK), Ocumivir1477.HK), Yongtai Biology6978.HK), Hype Pharma9989.HK), Kechuang Pharmaceutical9939.HK), Peijia Medical (9996.HK), Kangfang Biology9926.HK), Novartis HealthCare (9969.HK), Celestial BeingsIMAB.NASDAQ), Kanglonghua Cheng3759.HK), China Antibody3681.HK), Dongyao Pharmaceutical1875.HK), Yasheng Medicine6855.HK), Fosun Pharma (2696.HK), HensonPharmaceuticals3692.HK), Mabotech Pharmaceuticals2181.HK), Founder Holdings1521.HK), Viva Biology1873.HK), CStone Pharmaceuticals2616.HK), Junshi Biology1877.HK), WuXi AppTec (2359.HK), Innovent Biologics1801.HK), Hualing Medicine2552.HK), BeiGene (6160.HK), Gelifarmaceuticals1672.HK), WuXi AppTec Biologics2269.HK), China Resources Medicine3320.HK), Yakult Scientific & Pharmaceutical2633.HK), and Huang China MedicineHCM.NASDAQ), Biotechnology1548.HK),BBILife Sciences1035.HK) and so on. In terms of the number of submissions, Frost & Sullivan's healthcare team in Hong Kong is involved inIPO listingMaintain an absolute leading position,2018till2021Year after year, it has always ranked first in market share.

since2019year7Since the listing of the first batch of companies on the Sci-tech Innovation Board, Frost & Sullivan reports have also been widely referenced in the prospectuses of leading Sci-tech Innovation Board-listed companies, including: MicroPort Neurosurgery (688351.SH), Mengke Pharmaceutical688373.SH), Yifang Biology688382.SH), Jicui Pharmaceutical Health (688046.SH), Haiscot Biopharmaceuticals688302.SH), Rongchang Biology688331.SH), Rendu Biology688193.SH), Capital Medical Group Holdings (688197.SH), and Yuanbiotech (688238.SH), YASIN Security688225.SH), Xidiwei688173.SH), MyWay Biotechnology688062.SH), Yarong Medicine688176.SH), BeiGene (688235.SH), Jiahemeikang688246.SH), DiZhe Medicine688192.SH), Novozymes688105.SH), Chengda Biology688739.SH), Gecko Micro688728.SH), Huaxi Biology688363.SH), Junshi Biology688180.SH), Zhejiang Genomics & Therapeutics Co., Ltd.688266.SH), Bai'ao Tai688177.SH), SinoCell (688520.SH) and other institutions are considered one of the most powerful, professional, and influential industry research organizations in the sector. We aim to work with enterprises to understand industry trends, seize development opportunities, jointly promote innovation and upgrading of China's big health industry, and build a healthy future.